glp 1 agonist risks The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action The GLP-1 Agonists and Obesity:

Cabou C, Burcelin R

Torley D, Bellus GA, Munro CS

Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)

The availability of trained healthcare professionals and advanced facilities enables hospitals to safely initiate and adjust GLP-1 treatments, especially injectable forms like Semaglutide and Tirzepatide

Conclusions This study highlights substantial demand for GLP-1 and GLP-1/GIP medications to support weight loss in Great Britain

These CVOT findings are supported by a real-world study performed in over 3 million patients with T2DM from the United States, in which patients treated with SGLT2is did not have a higher risk of any or lower amputation compared with incretins or other glucose-lowering agents [77]